Company news

Neurocrine Biosciences, Inc. news in 2022

Neurocrine Biosciences, Inc.'s news releases, calls and decks from 2022, newest first.

View company

Neurocrine Biosciences Announces U.S. FDA Accepts Supplemental New Drug Application for Valbenazine as a Treatment for Chorea Associated with Huntington Disease

December 21, 2022

Neurocrine Biosciences Provides Update on Phase 2 Study of NBI-827104 in Pediatric Patients with Epileptic Encephalopathy with Continuous Spike-and-Wave During Sleep

December 5, 2022

Neurocrine Biosciences Presents Demographic and Clinical Characteristics Data of Pediatric Patients with SCN8A-Related Epilepsies at AES 2022

December 1, 2022

Neurocrine Biosciences to Present at Upcoming Healthcare Conferences

November 7, 2022

Neurocrine Biosciences Presents Data on In Vitro Dissolution Performance of INGREZZA® (valbenazine) Capsules at the American Society of Consultant Pharmacists (ASCP) 2022 Annual Meeting

November 2, 2022

Neurocrine Biosciences Presents Additional Phase 3 Data for KINECT-HD Study Evaluating Valbenazine for Chorea Associated with Huntington Disease at HSG 2022

November 2, 2022

Neurocrine Biosciences Reports Third Quarter 2022 Financial Results and Raises 2022 INGREZZA Sales Guidance

October 31, 2022

Neurocrine Biosciences Initiates Phase 2 Clinical Study Evaluating NBI-1117568 in Adults with Schizophrenia

October 26, 2022

Neurocrine Biosciences Presents Real-World Parkinson's Disease Patient Characteristics From ONGENTYS® (opicapone) Open-Label Study at ANA2022

October 23, 2022

Neurocrine Biosciences Presents Data on Benztropine Use Among People Treated with Antipsychotics at the 2022 American Psychiatric Nurses Association (APNA) Annual Conference

October 18, 2022

Neurocrine Biosciences Announces Conference Call and Webcast of Third Quarter 2022 Financial Results

October 10, 2022

Neurocrine Biosciences Appoints Dr. Ingrid Delaet as Chief Regulatory Officer

September 28, 2022

Neurocrine Biosciences Presents INGREZZA® (valbenazine) Data on Sustained Treatment Response at Psych Congress 2022

September 18, 2022

Neurocrine Biosciences to Present Study Findings on Evolving Tardive Dyskinesia Education Needs of Physicians at the 2022 MDS International Congress

September 14, 2022

Neurocrine Biosciences Presents New Post-Hoc Analysis of ONGENTYS® (opicapone) Capsules Effect on COMT Activity at the 2022 MDS International Congress

September 14, 2022

Parkinson & Movement Disorder (PMD) Alliance and Neurocrine Biosciences Announce New Survey Results Revealing the Significant Impact OFF Time Has on People with Parkinson's Disease and Their Care Partners

September 11, 2022

Neurocrine Biosciences to Present at the Morgan Stanley 20th Annual Global Healthcare Conference

September 5, 2022

Neurocrine Biosciences Reports Second Quarter 2022 Financial Results and Raises 2022 INGREZZA Sales Guidance

August 3, 2022

Neurocrine Biosciences Announces Conference Call and Webcast of Second Quarter 2022 Financial Results

July 13, 2022

Neurocrine Biosciences Presents Data on Treatment of Adolescent Patients with Classic Congenital Adrenal Hyperplasia at ENDO 2022

June 12, 2022

Neurocrine Biosciences to Present at the Goldman Sachs 43rd Annual Global Healthcare Conference

June 7, 2022

Neurocrine Biosciences Presents Data on Sleep Disturbances and OFF Time in Patients with Parkinson's Disease and Motor Fluctuations at SLEEP 2022

June 5, 2022

Neurocrine Biosciences Honored at CARES Foundation 22nd Anniversary Gala

June 5, 2022

Neurocrine Biosciences Announces Repurchase of Convertible Notes

May 23, 2022

Neurocrine Biosciences Presents New INGREZZA® (valbenazine) Data on Tardive Dyskinesia Improvement and Stability of Psychiatric Symptoms at American Psychiatric Association Annual Meeting 2022

May 22, 2022

Neurocrine Biosciences Receives Orphan Drug Designation for Valbenazine as a Treatment for Chorea Associated with Huntington Disease

May 11, 2022

Neurocrine Biosciences Reports First Quarter 2022 Financial Results and Reiterates 2022 Financial Guidance

May 3, 2022

Neurocrine Biosciences to Present at the Bank of America Securities 2022 Healthcare Conference

May 2, 2022

Neurocrine Biosciences Honors Mental Health Awareness Month and Fifth Anniversary of Tardive Dyskinesia Awareness Week

May 1, 2022

Neurocrine Biosciences Announces Conference Call and Webcast of First Quarter 2022 Financial Results

April 12, 2022

Neurocrine Biosciences Presents Phase 3 Data for KINECT-HD Study Evaluating Valbenazine for Chorea Associated with Huntington Disease at AAN 2022

March 31, 2022

Neurocrine Biosciences to Present Data on Treatment Patterns and Unmet Needs in Adult and Pediatric Patients Living with Classic Congenital Adrenal Hyperplasia at AMCP 2022

March 27, 2022

Neurocrine Biosciences Announces Regulatory Approval of Dysval® (valbenazine) for the Treatment of Tardive Dyskinesia in Japan

March 27, 2022

Neurocrine Biosciences to Present Data from Movement Disorder Portfolio at the American Academy of Neurology 2022 In-Person and Virtual Annual Meeting

March 23, 2022

Neurocrine Biosciences to Present at Stifel 2022 CNS Days

March 20, 2022

Neurocrine Biosciences Reports Fourth Quarter and Fiscal 2021 Financial Results and Provides Financial Expectations for Fiscal 2022

February 10, 2022

Neurocrine Biosciences Announces Conference Call and Webcast of Fourth Quarter and Year-End 2021 Financial Results

January 24, 2022

Neurocrine Biosciences Provides Preliminary Fourth Quarter and Full-Year 2021 Net Product Sales Results and Future Program Milestones

January 5, 2022

Neurocrine Biosciences to Present at the 40th Annual J.P. Morgan Healthcare Conference

January 2, 2022

Calls in 2022

Decks in 2022